AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
LIPID-LOWERING THERAPY IN CAD PATIENTS AT ACADEMIC MEDICAL-CENTERS - UNDERTREATMENT AND EVIDENCE OF A GENDER-GAP
Authors: MILLER M BYINGTON RP HUNNINGHAKE D FURBERG CD PITT B
Citation: M. Miller et al., LIPID-LOWERING THERAPY IN CAD PATIENTS AT ACADEMIC MEDICAL-CENTERS - UNDERTREATMENT AND EVIDENCE OF A GENDER-GAP, Journal of the American College of Cardiology, 31(2), 1998, pp. 186-186
OUTCOME RESULTS OF THE FOSINOPRIL VERSUS AMLODIPINE CARDIOVASCULAR EVENTS RANDOMIZED TRIAL (FACET) IN PATIENTS WITH HYPERTENSION AND NIDDM
Authors: TATTI P PAHOR M BYINGTON RP DIMAURO P GUARISCO R STROLLO G STROLLO F
Citation: P. Tatti et al., OUTCOME RESULTS OF THE FOSINOPRIL VERSUS AMLODIPINE CARDIOVASCULAR EVENTS RANDOMIZED TRIAL (FACET) IN PATIENTS WITH HYPERTENSION AND NIDDM, Diabetes care, 21(4), 1998, pp. 597-603
ISRADIPINE IN PREDIABETIC HYPERTENSIVE SUBJECTS
Authors: BYINGTON RP FURBERG CD CRAVEN TE PAHOR M SOWERS JR
Citation: Rp. Byington et al., ISRADIPINE IN PREDIABETIC HYPERTENSIVE SUBJECTS, Diabetes care, 21(12), 1998, pp. 2103-2110
HMG-COA REDUCTASE INHIBITOR THERAPY AND STROKE RISK REDUCTION - AN ANALYSIS OF CLINICAL-TRIALS DATA (VOL 138, PG 11, 1998)
Authors: CROUSE JR BYINGTON RP FURBERG CD
Citation: Jr. Crouse et al., HMG-COA REDUCTASE INHIBITOR THERAPY AND STROKE RISK REDUCTION - AN ANALYSIS OF CLINICAL-TRIALS DATA (VOL 138, PG 11, 1998), Atherosclerosis (Amsterdam), 140(1), 1998, pp. 193-194
HMG-COA REDUCTASE INHIBITOR THERAPY AND STROKE RISK REDUCTION - AN ANALYSIS OF CLINICAL-TRIALS DATA
Authors: CROUSE JR BYINGTON RP FURBERG CD
Citation: Jr. Crouse et al., HMG-COA REDUCTASE INHIBITOR THERAPY AND STROKE RISK REDUCTION - AN ANALYSIS OF CLINICAL-TRIALS DATA, Atherosclerosis, 138(1), 1998, pp. 11-24
LOWERING OF CHOLESTEROL LEVELS AND THE RISK OF STROKE - REPLY
Authors: CROUSE JR BYINGTON RP HOEN HM FURBERG CD
Citation: Jr. Crouse et al., LOWERING OF CHOLESTEROL LEVELS AND THE RISK OF STROKE - REPLY, Archives of internal medicine, 158(1), 1998, pp. 99-99
ISRADIPINE, RAISED GLYCOSYLATED HEMOGLOBIN, AND RISK OF CARDIOVASCULAR EVENTS
Authors: BYINGTON RP CRAVEN TE FURBERG CD PAHOR M
Citation: Rp. Byington et al., ISRADIPINE, RAISED GLYCOSYLATED HEMOGLOBIN, AND RISK OF CARDIOVASCULAR EVENTS, Lancet, 350(9084), 1997, pp. 1075-1076
THE TICENTER-ISRADIPINE-DIURETIC-ATHEROSCLEROSIS-STUDY (MIDAS)
Authors: APPLEGATE WB FURBERG CD BYINGTON RP GRIMM R
Citation: Wb. Applegate et al., THE TICENTER-ISRADIPINE-DIURETIC-ATHEROSCLEROSIS-STUDY (MIDAS), JAMA, the journal of the American Medical Association, 277(4), 1997, pp. 297-297
RESULTS OF THE FOSINOPRIL AMLODIPINE CARDIOVASCULAR EVENTS TRIAL (FACET) IN HYPERTENSIVE PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS (NIDDM)
Authors: TATTI P PAHOR M BYINGTON RP DIMAURO P GUARISCO R STROLLO F
Citation: P. Tatti et al., RESULTS OF THE FOSINOPRIL AMLODIPINE CARDIOVASCULAR EVENTS TRIAL (FACET) IN HYPERTENSIVE PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS (NIDDM), Circulation, 96(8), 1997, pp. 4286-4286
REDUCTASE INHIBITOR MONOTHERAPY AND STROKE PREVENTION
Authors: CROUSE JR BYINGTON RP HOEN HM FURBERG CD
Citation: Jr. Crouse et al., REDUCTASE INHIBITOR MONOTHERAPY AND STROKE PREVENTION, Archives of internal medicine, 157(12), 1997, pp. 1305-1310
RATIONALE, DESIGN, AND BASE-LINE CHARACTERISTICS OF THE PROSPECTIVE RANDOMIZED EVALUATION OF THE VASCULAR EFFECTS OF NORVASC TRIAL (PREVENT)
Authors: BYINGTON RP MILLER ME HERRINGTON D RILEY W PITT B FURBERG CD HUNNINGHAKE DB MANCINI GBJ
Citation: Rp. Byington et al., RATIONALE, DESIGN, AND BASE-LINE CHARACTERISTICS OF THE PROSPECTIVE RANDOMIZED EVALUATION OF THE VASCULAR EFFECTS OF NORVASC TRIAL (PREVENT), The American journal of cardiology, 80(8), 1997, pp. 1087
MAXIMIZING RECRUITMENT EFFORTS IN A DRUG LIPID-LOWERING TRIAL WITH DIETARY INTERVENTION TO LOWER LDL CHOLESTEROL
Authors: DOLECEK TA BRADHAM KH ESPELAND MA MARGITIC SE BYINGTON RP HOEN H KAPPELLE LJ
Citation: Ta. Dolecek et al., MAXIMIZING RECRUITMENT EFFORTS IN A DRUG LIPID-LOWERING TRIAL WITH DIETARY INTERVENTION TO LOWER LDL CHOLESTEROL, Controlled clinical trials, 17(1), 1996, pp. 33-45
REDUCTASE INHIBITOR MONOTHERAPY PREVENTS STROKE
Authors: CROUSE JR BYINGTON RP FURBERG CD
Citation: Jr. Crouse et al., REDUCTASE INHIBITOR MONOTHERAPY PREVENTS STROKE, Circulation, 94(8), 1996, pp. 3158-3158
EFFECT OF CHOLESTEROL-LOWERING MEDICATIONS ON PROGRESSION OF MILD ATHEROSCLEROTIC LESIONS OF THE CAROTID ARTERIES AND ON THE RISK OF STROKE
Authors: ADAMS HP BYINGTON RP HOEN H DEMPSEY R FURBERG CD
Citation: Hp. Adams et al., EFFECT OF CHOLESTEROL-LOWERING MEDICATIONS ON PROGRESSION OF MILD ATHEROSCLEROTIC LESIONS OF THE CAROTID ARTERIES AND ON THE RISK OF STROKE, Cerebrovascular diseases, 5(3), 1995, pp. 171-177
REVERSING RISK IN CORONARY-DISEASE
Authors: BYINGTON RP FURBERG CD
Citation: Rp. Byington et Cd. Furberg, REVERSING RISK IN CORONARY-DISEASE, Lancet, 345(8945), 1995, pp. 330-330
REDUCTION IN CARDIOVASCULAR EVENTS DURING PRAVASTATIN THERAPY - POOLED ANALYSIS OF CLINICAL EVENTS OF THE PRAVASTATIN ATHEROSCLEROSIS INTERVENTION PROGRAM
Authors: BYINGTON RP JUKEMA JW SALONEN JT PITT B BRUSCHKE AV HOEN H FURBERG CD MANCINI J
Citation: Rp. Byington et al., REDUCTION IN CARDIOVASCULAR EVENTS DURING PRAVASTATIN THERAPY - POOLED ANALYSIS OF CLINICAL EVENTS OF THE PRAVASTATIN ATHEROSCLEROSIS INTERVENTION PROGRAM, Circulation, 92(9), 1995, pp. 2419-2425
RESULTS OF THE PRIMARY OUTCOME MEASURE AND CLINICAL EVENTS FROM THE ASYMPTOMATIC CAROTID-ARTERY PROGRESSION STUDY
Authors: PROBSTFIELD JL MARGITIC SE BYINGTON RP ESPELAND MA FURBERG CD
Citation: Jl. Probstfield et al., RESULTS OF THE PRIMARY OUTCOME MEASURE AND CLINICAL EVENTS FROM THE ASYMPTOMATIC CAROTID-ARTERY PROGRESSION STUDY, The American journal of cardiology, 76(9), 1995, pp. 47-53
PRAVASTATIN, LIPIDS, AND ATHEROSCLEROSIS IN THE CAROTID ARTERIES (PLAC-II)
Authors: BYINGTON RP FURBERG CD CROUSE JR ESPELAND MA BOND MG
Citation: Rp. Byington et al., PRAVASTATIN, LIPIDS, AND ATHEROSCLEROSIS IN THE CAROTID ARTERIES (PLAC-II), The American journal of cardiology, 76(9), 1995, pp. 54-59
REDUCTION IN CORONARY EVENTS DURING TREATMENT WITH PRAVASTATIN
Authors: FURBERG CD PITT B BYINGTON RP PARK JS MCGOVERN ME
Citation: Cd. Furberg et al., REDUCTION IN CORONARY EVENTS DURING TREATMENT WITH PRAVASTATIN, The American journal of cardiology, 76(9), 1995, pp. 60-63
DESIGN, RATIONALE, AND BASE-LINE CHARACTERISTICS OF THE PROSPECTIVE PRAVASTATIN POOLING (PPP) PROJECT - A COMBINED ANALYSIS OF 3 LARGE-SCALE RANDOMIZED TRIALS - LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC-DISEASE (LIPID), CHOLESTEROL AND RECURRENT EVENTS (CARE), AND WESTOF SCOTLAND CORONARY PREVENTION STUDY (WOSCOPS)
Authors: FURBERG C BYINGTON RP BAKER JL COBBE SM DAVIS B FORD I GLASZIOU P HAWKINS CM KEECH AC MACMAHON S MOYE L PACKARD C PFEFFER MA SACKS FM SHEPHERD J SIMES J TONKIN A MELLIES M MCGOVERN M NICHOLAS S ANDERSON S PARK JS BARNHART M FORTUNATO J
Citation: C. Furberg et al., DESIGN, RATIONALE, AND BASE-LINE CHARACTERISTICS OF THE PROSPECTIVE PRAVASTATIN POOLING (PPP) PROJECT - A COMBINED ANALYSIS OF 3 LARGE-SCALE RANDOMIZED TRIALS - LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC-DISEASE (LIPID), CHOLESTEROL AND RECURRENT EVENTS (CARE), AND WESTOF SCOTLAND CORONARY PREVENTION STUDY (WOSCOPS), The American journal of cardiology, 76(12), 1995, pp. 899-905
PRAVASTATIN, LIPIDS, AND ATHEROSCLEROSIS IN THE CAROTID ARTERIES (PLAC-II)
Authors: CROUSE JR BYINGTON RP BOND MG ESPELAND MA CRAVEN TE SPRINKLE JW MCGOVERN ME FURBERG CD
Citation: Jr. Crouse et al., PRAVASTATIN, LIPIDS, AND ATHEROSCLEROSIS IN THE CAROTID ARTERIES (PLAC-II), The American journal of cardiology, 75(7), 1995, pp. 455-459
PRAVASTATIN, LIPIDS, AND ATHEROSCLEROSIS IN THE CAROTID ARTERIES (VOL75, PG 455, 1995)
Authors: CROUSE JR BYINGTON RP BOND MG ESPELAND MA CRAVEN TE SPRINKLE JW MCGOVERN ME FURBERG CD
Citation: Jr. Crouse et al., PRAVASTATIN, LIPIDS, AND ATHEROSCLEROSIS IN THE CAROTID ARTERIES (VOL75, PG 455, 1995), The American journal of cardiology, 75(12), 1995, pp. 862-862
LESSONS LEARNED FROM CLINICAL-TRIALS WITH ULTRASOUND END-POINTS
Authors: FURBERG CD BYINGTON RP CRAVEN TE
Citation: Cd. Furberg et al., LESSONS LEARNED FROM CLINICAL-TRIALS WITH ULTRASOUND END-POINTS, Journal of internal medicine, 236(5), 1994, pp. 575-580
FEATURES OF THE NUTRIENT DATABASE AND ANALYSIS SYSTEM FOR THE MODIFICATION OF DIET IN RENAL-DISEASE STUDY
Authors: GILLIS BP CAGGIULA AW JONES FL MAURER E MEEHAN RM YAMAMOTO ME STRIKER GE KUSEK JW AGODOA LY ANDERSON A KLAHR S LEVEY AS VARDAMAN M BURKART TJM FURBERG CD FELTS J MOORE M ROCCO M WARREN S BEARDEN B STARKEY C DOLECEK TA HARVEY J POOLE D DAHLQUIST S DOROSHENKO L BRADHAM K WEST D AGOSTINO J COLE LR BAKER B HAIRSTON K LAZARUS M STEINMAN TTI SEIFTER JJ DESMOND MA FIORENZO MA CHIAVACCI AT METALIDES T KORZECRAMIREZ D GOULD SL PICKETT V PORUSH JG FAUBERT PF SPITALEWITZ S FAUBERT JS ZIMMER GS SAUM DL BLOCK M WOEL J ROSE MF DENNIS VW SCHWAB TSJ MINDA SA CONDON SM JENKS BF ECKARD L GEDON G MITCH WE MARONI BJ ENGLAND BK SOUCIE M PEDERSEN MF AKPELE L CALLAHN P HALL B KOPPLE JD ADLER SG HIRSCHBERG R DICHIRO J SNIDER K DEVINE W MCKAY S MCDONALD JM CARTER J NELSON WJ COGGINS CH DWYER JT MCLAUGHLIN ML GRONICH J KING AJ STOLLAR C RAIZMAN D CASTALDO L DESIMONE D EFSTATHION A YONKER K FINE JA HUGGINS N MARTIN A BALDI S MOLESKE C FURLONG D HEBERT LA NAHMAN NS DRIVER V COSIO MJ HARTMAN JA LEVY CS LONDERGAN D GILLIGAN M BECKMAN TJ MILLER J SMITH E TISHER CC PETERSON JC WINGO CS FINLAY A PARRIS ES IVEY G GREGORY P HOFFINGER R GARCIA D PRESTON C HUNSICKER LG BERTOLATUS JA LIM V SNETSELAAR L WELCH B BROOKS LL HOLLINGER DL LICHTY I MUELLER DK EASTIN S TANNA A STEELE J RIECK K BOURGOIGNIE J ROTH D GREEN DF DEVALDERRAMA CO MERRILL D DEVELASCO A GARCON M ROJAS C ZARAGOZA M BARTON A MASSRY SG AKMAL M FADDA G SMORGORZERSKI M KIEFER S RAUCH S EYERMAN M KIGAWA L LIFSCHITZ MD NOLAN CR GOUGE S BAKRIS G YOUNG E ARMES C WARNER C TANSEY A FIORES MO DELEA CS TESCHAN PE HAKIM RM BREYER JA SCHULMAN G ROGERS NL POWERS SN MCLEROY S FISCHER S DEERE M CUTLER EM BECK GJ WILLIAMS GW GASSMAN JJ GREENE T SCHLUCHTER MD BERG RL BROWN M CHU L DRABIK MJ FATICA KJ LAMBDIN KE LEATHERMAN JR MCPHERSON JA MIDCALF V MOORE B SWINDERMAN DM WEBB L YANCHAR KA MILAS NC AMOROSO WP AVERBACH FA COYNE T GILLIS B MAURER EA MEEHAN RJ NAUJELIS JA OLSON MB SCHERCH LK STANO E CHUMLEA WC WING RR STEGINK LD BRUMMEL MC VANLENTE F WALETZKY JA ERDEI LM SOUTH CA SPAGNOLA C OLAUGHLIN C PROUDFIT WL UNDERWOOD DA HALL PM ROLIN HA PEXA DS JONES E BASCH M DAMICO G DIRKS JH GRANTHAM J HARPER AE PETERS K STEIN JH PELLEGRINO ED VANYPERSELE C MYERS BD GRIZZLE JE HAWKINS CM HOLLIDAY MA RUDMAN D YOUNG DS YOUNG V LUKE R KAPLAN RM BYINGTON RP
Citation: Bp. Gillis et al., FEATURES OF THE NUTRIENT DATABASE AND ANALYSIS SYSTEM FOR THE MODIFICATION OF DIET IN RENAL-DISEASE STUDY, Controlled clinical trials, 15(1), 1994, pp. 44-58
PREDICTORS OF CAROTID ATHEROSCLEROSIS PROGRESSION
Authors: BYINGTON RP EVANS GW APPLEGATE WB IFURBERG CD
Citation: Rp. Byington et al., PREDICTORS OF CAROTID ATHEROSCLEROSIS PROGRESSION, Circulation, 90(4), 1994, pp. 127-1227
Risultati: 1-25 | 26-31